Apr. 7 at 2:30 PM
$CDXS So what do we know as fact right now:
(1) Codexis is involved in with
$MRK on the manufacturing of enlicitide (M-0616) through a biocatalytic process to produce trans-3-hydroxy-l-proline, a critical intermediate for synthesizing the oral PCSK9 inhibitor enlicitide decanoate (MK-0616), developed by Merck.
(2) Codexis and
$BCHMF are involved with
$ALNY through the manufacturing of Vutrisiran which is currently going through an FDA fast track for the treatment of patients with transthyretin-mediated amyloidosis with cardiomyopathy/ATTR-CM.
That right there ALONE makes this worth $
$3.50+.
MANY additional partnerships in the works!
